Global Analgesics Market Report to 2026 – Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Analgesics – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Amid the COVID-19 crisis, the global market for Analgesics estimated at US$45.1 Billion in the year 2020, is projected to reach a revised size of US$59.2 Billion by 2026, growing at a CAGR of 4.7% over the analysis period.

Prescription, one of the segments analyzed in the report, is projected to grow at a 4.4% CAGR to reach US$37.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the OTC segment is readjusted to a revised 5.1% CAGR for the next 7-year period. This segment currently accounts for a 38.2% share of the global Analgesics market.

The U.S. Market is Estimated at $15.2 Billion in 2021, While China is Forecast to Reach $8.2 Billion by 2026

The Analgesics market in the U.S. is estimated at US$15.2 Billion in the year 2021. The country currently accounts for a 32.76% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$8.2 Billion in the year 2026 trailing a CAGR of 6.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR while Rest of European market (as defined in the study) will reach US$8.8 Billion by the close of the analysis period.

Opioids Segment to Reach $18.4 Billion by 2026

Opioid analgesic drugs represent the gold standard in pain relieving treatment of critically ill patients across disease segments, including COVID-19. Fentanyl, morphine, and hydromorphone are among the most commonly used IV opioid analgesic drugs in the ICU settings for COVID as well as non-COVID patients. Global Opioids segment is estimated at US$14.9 Billion in 2020, and is projected to reach US$18.4 Billion by 2026 reflecting a compounded annual growth rate of 3.7% over the analysis period. United States constitutes the largest regional market for Opioids segment, accounting for 29.9% of the global sales in 2020. China is poised to register the fastest compounded annual growth rate of 5.2% over the analysis period, to reach US$2.6 Billion by 2026.

Select Competitors (Total 146 Featured) –

• Amneal Pharmaceuticals Inc
• Apotex Inc
• AstraZeneca Plc
• Aurobindo Pharma Limited
• Bausch Health Companies Inc.
• Bayer AG
• Cipla Limited
• Eli Lilly and Company
• Endo International plc
• F. Hoffmann-La Roche AG
• Fresenius Kabi AG
• GlaxoSmithKline PLC
• Hikma Pharmaceuticals PLC
• Iroko Pharmaceuticals, LLC
• Johnson & Johnson
• Lupin Limited
• Novartis AG
• Reckitt Benckiser Group plc
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Analgesics – Global Key Competitors Percentage Market Share in 2022 (E)
• Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
• Impact of Covid-19 and a Looming Global Recession
• A Prelude to Analgesics
• Analgesics: Perfect Therapeutic Options to Solve Mild to Crippling Pain
• Key Segments
• Opioid Analgesics
• Non-Opioid Analgesics
• NSAIDs
• Topical NSAIDs
• Others
• Acetaminophen
• Adjuvant Analgesics
• Impact of COVID-19 on Analgesics
• NSAIDs
• NSAIDs Tend to Decrease Effectiveness of COVID-19 Vaccines, States a Yale University Study
• Opioid
• Acetaminophen
• Global Analgesics Market to Witness Rapid Growth
• Drugs Indicated for Pain Management
• The US and Europe Represent the Largest Regions, Asia-Pacific to Witness fastest Growth
• Non-Opioids: Fastest Growing Category
• Competition
• Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

• Growing Aging Population & Increasing Burden of Chronic Diseases Spurs
• Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
• Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
• Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
• Growing Incidence of Cancer and the Associated Pain to Drive the Analgesics Market
• Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
• Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
• Number of New Cancer Cases and Deaths (in Million) by Region for 2018
• Advancements in Design and Delivery of Analgesic Drugs
• Development of Safer Opioids with More Safer Profiles
• Drug Pipeline with Efficacious Drugs
• OTC Analgesics Market to Witness Fastest Growth
• Topical Analgesics Market Holds Significant Share
• Combination Therapies Gain Prominence
• A Few Novel Analgesic Products under Development
• E-commerce Platforms Strengthen Pharmaceutical Distribution in Crisis Period
• Neuropathic Pain Management: Market with High Potential
• Migraine Market: A Core Vertical in CNS Pain Management
• Migraine Care: Select Patent Expiries (2013-2015)
• Reyvow, Eli Lilly’s Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
• Three New Migraine Drugs Obtain FDA Approval
• Eli Lilly’s Emgality Receives FDA Approval
• Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/iejhja

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900